Genelux Reports Promising Interim Results for Olvi-Vec in Lung Cancer Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: NASDAQ.COM
- Small Cell Lung Cancer Progress: In the Phase 1b/2 study conducted in China, Genelux's Olvi-Vec demonstrated a 33% overall response rate and a 67% disease control rate, with tumor shrinkage up to 85% in the highest-dose cohort, indicating the therapy's potential in small cell lung cancer treatment and possibly providing new options for future therapies.
- Non-Small Cell Lung Cancer Efficacy: In the Phase 2 VIRO-25 study in the U.S., five evaluable patients exhibited a 60% disease control rate, with tumor reductions ranging from 8.9% to 22.7%, showcasing Olvi-Vec's effectiveness in treating non-small cell lung cancer and potentially offering new hope for patients.
- Good Tolerability: Olvi-Vec was generally well tolerated in both trials, indicating its safety in clinical applications and laying the groundwork for larger-scale clinical trials in the future.
- Future Data Expectations: Genelux anticipates releasing additional interim data from both trials throughout 2026, with topline results from a Phase 3 ovarian cancer trial expected in the second half of 2026, which will provide crucial insights for the company's future R&D direction and market strategy.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GNLX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GNLX
Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.50 USD with a low forecast of 16.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.760
Low
16.00
Averages
22.50
High
31.00
Current: 2.760
Low
16.00
Averages
22.50
High
31.00
About GNLX
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genelux Corporation to Host Virtual Fireside Chat on January 19, 2026
- Executive Participation: Genelux Corporation's President and CEO Thomas Zindrick, along with other executives, will participate in a virtual fireside chat on January 19, 2026, hosted by Boris Peaker, PhD, to enhance investor understanding of the company's clinical advancements.
- Clinical Trial Progress: Genelux's Olvi-Vec is undergoing multiple clinical trials, including a Phase 3 registrational trial for platinum-resistant ovarian cancer and a Phase 2 trial for non-small-cell lung cancer, showcasing the company's active exploration in tumor immunotherapy.
- Expansion into China: Olvi-Vec is also being evaluated in a multi-center Phase 1b/2 trial in China for recurrent small-cell lung cancer, indicating Genelux's strategic positioning in international markets.
- CHOICE™ Platform Advantage: The core of Genelux's R&D is its proprietary CHOICE™ platform, which supports the development of various isolated and engineered oncolytic immunotherapeutic product candidates, enhancing the company's competitiveness in the biopharmaceutical sector.
Continue Reading
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
Continue Reading